Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. Issue 17 (20th April 2022)

• Record Type: Journal Article
• Authors: Yngvadottir, Bryndis; Andreou, Avgi; Bassaganyas, Laia; Larionov, Alexey; Cornish, Alex J; Chubb, Daniel; Saunders, Charlie N; Smith, Philip S; Zhang, Huairen; Cole, Yasemin; Research Consortium, Genomics England; Larkin, James; Browning, Lisa; Turajlic, Samra; Litchfield, Kevin; Houlston, Richard S; Maher, Eamonn R
• Is Part Of: Human molecular genetics. Volume 31:Issue 17(2022)
• Page Start: 3001
• Page End: 3011
• Publication Date: 2022-04-20
• Subjects: Human molecular genetics -- Periodicals; Human chromosome abnormalities -- Periodicals; 572.8
• DOI: 10.1093/hmg/ddac089
• Languages: English
• ISSNs: 0964-6906

Abstract

Abstract: Renal cell carcinoma (RCC) occurs in a number of cancer predisposition syndromes, but the genetic architecture of susceptibility to RCC is not well defined. We investigated the frequency of pathogenic and likely pathogenic (P/LP) germline variants in cancer susceptibility genes (CSGs) within a large series of unselected RCC participants. Whole-genome sequencing data on 1336 RCC participants and 5834 controls recruited to the UK 100 000 Genomes Project, a nationwide multicentre study, was analyzed to identify rare P/LP short variants (single nucleotide variants and insertions/deletions ranging from 1 to 50 base pairs) and structural variants in 121 CSGs. Among 1336 RCC participants [mean: 61.3 years (±12 SD), range: 13–88 years; 64% male], 85 participants [6.4%; 95% CI (5.1, 7.8)] had one or more P/LP germline variant in a wider range of CSGs than previously recognized. A further 64 intragenic variants in CSGs previously associated with RCC were classified as a variant of uncertain significance (VUS) (24 'hot VUSs') and were considered to be of potential clinical relevance as further evaluation might results in their reclassification. Most patients with P variants in well-established CSGs known to predispose to renal cell carcinoma (RCC-CSGs) were aged <50 years. Burden test analysis for filtered variants in CSGs demonstrated a significant excess of CHEK2 variants in European RCC participants compared with the healthy European controls ( P = 0.0019). Approximately, 6% of the patients with RCC unselected for family history have a germline variant requiring additional follow-up analysis. To improve diagnostic yield, we suggest expanding the panel of RCC-CSGs tested to include CHEK2 and all SDH x subunits and raising the eligibility criteria for age-based testing.